| S7498 |
DDR1-IN-1
|
DDR1-IN-1 is a potent and selective discoidin domain receptor 1 (DDR1) receptor tyrosine kinase inhibitor with IC50 of 105 nM, about 3-fold selectivity over DDR2.
|
-
Cell Genomics, 2024, 100487
-
Cell Genom, 2024, 4(2):100487
-
EMBO Molecular Medicine, 2022, e11814
|
|
| E1825 |
7rh
|
7rh (DDR1-IN-2) is a potent inhibitor of discoidin domain receptor 1 (DDR1) with an IC50 of 13.1 nM. It also inhibits DDR2 less effectively with an IC50 of 203 nM. It also exhibits antitumor effects in nasopharyngeal carcinoma cells.
|
-
International Journal of Molecular Sciences, 2020, 4956
|
|
| S6817 |
VU6015929
|
VU6015929 is a selective Discoidin Domain Receptor 1/2 (DDR1/2) inhibitor with IC50 of 4.67 nM and 7.39 nM for DDR1 and DDR2, respectively. This compound potently inhibits collagen-IV production.
|
|
|
| S7014 |
Merestinib (LY2801653)
|
Merestinib (LY2801653) is a type-II ATP competitive, slow-off inhibitor of Met (c-Met) tyrosine kinase with a dissociation constant (Ki) of 2 nM, a pharmacodynamic residence time (Koff) of 0.00132 min(-1) and t1/2 of 525 min. This compound also inhibits MST1R, AXL, ROS1, MKNK1/2, FLT3, MERTK, DDR1 and DDR2 with IC50 of 11 nM, 2 nM, 23 nM, 7 nM, 7 nM, 10 nM, 0.1 nM and 7 nM, respectively.
|
-
Mol Oncol, 2025, 19(8):2366-2387
-
Molecular Oncology, 2025, 2366-2387
-
NPJ Breast Cancer, 2024, 10(1):65
|
|
| E0621 |
FGFR1/DDR2 inhibitor 1
|
FGFR1/DDR2 inhibitor 1 is an inhibitor of fibroblast growth factor receptor 1 (FGFR1) and discoidin domain receptor 2 (DDR2).
|
|
|